The present disclosure provides methods and compositions related to Natural Killer T cells that are engineered to knock down the expression of one or more endogenous major histocompatibility complex (MHC) gene. The present disclosure also provides engineered CAR NKT cells that resist rejection by allogeneic immune cells both in vitro and in vivo.

Compositions containing micropeptides capable of modulating the accumulation of miRs involved in certain pathologies, and the use of these micropeptides for treating the certain pathologies. Also, methods of identifying these micropeptides modulating the accumulation of miRs involved in pathologies. Further, nuclei acids encoding those micropeptides that modulate the accumulation of miRs involved in pathologies.

Provided herein are placental stem cells that exhibit increased survival (“enhanced placental stem cells”), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.

Compositions and methods are provided for reprogramming dermal fibroblasts to exhibit vasculogenic properties including the ability to stimulate vasculogenesis in vivo. In accordance with one embodiment such compositions are used in conjunction with standard treatment for use on chronic wounds including in diabetic patients.

The present invention relates to a composition for inducing browning, a pharmaceutical composition for preventing or treating metabolic diseases, and a food composition for alleviating metabolic diseases, all of the compositions containing milk exosomes. In addition, the present invention relates to a method for inducing the differentiation of white adipocytes into beige adipocytes or brown adipocytes by treatment with the milk exosomes, and a method for treating obesity or metabolic diseases by administering the milk exosomes.

The present disclosure provides methods for generating induced cardiomyocytes by expression of selected microRNAs with MYOCD and ASCL1, or with MYOCD alone. Illustrative microRNAs include miR-133, miR-1, miR-19, and/or miR-20b. The present disclosure further provides gene-delivery vectors comprising one or more polynucleotides encoding a selected microRNA with YOCD, withMYOCD and ASCL1, with MYOCD-2A-ASCL1, or with ASCL1-2A-MYOCD. It further provides methods of using such compositions and vectors, or induced cardiomyocytes generated with these factors, for treating a heart condition.

Disclosed are compositions and methods related to recombinant cells expressing microRNA and an immunoglobulin gene.

Methods of providing populations of NKT and/or γδ T cells, and their use, e.g., in therapies such as cancer immunotherapy.

Embodiments disclosed here are production methods and compositions of engineered immune cells, such as B or T lymphocytes, from limited lineage myeloid progenitor cells, or from pluripotent stem cells, or from multilineage hematopoietic progenitor cells comprising the addition of various cell differentiation transcription factors and inhibiting epigenetic histone methylations in said cells.

The present invention relates to a non-viral iPSCs induction composition and the kits thereof. Specifically, it comprises a recombinant plasmid, and the recombinant plasmid is obtained by constructing the DNA sequences expressing the reprogramming factors POU5F1, SOX2, GLIS1, KLF4, MYCL and hsa-miR-302s into an episomal vector; The DNA sequence of hsa-miR-302s comprises one or more sequences selected from hsa-miR-302a, hsa-miR-302b, hsa-miR-302c and hsa-miR-302d. The induction composition is suitable for a highly safe and non-integrated induction reprogramming to obtain iPSCs, which reduces the risk of the clinical applications without an introduction of the high-risk reprogramming factors such as c-MYC, SV40-LT and TP53 inhibitors.